RhumbLine Advisers’s Zymeworks ZYME Stock Holding History

RhumbLine Advisers’s Portfolio ZYME Stock Details ZYME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.96M	Sell	75,066 -333	-0.4%	-$8.46K	﹤0.01%	1945
2026 Q1	$1.89M	Sell	75,399 -99	-0.1%	-$2.34K	﹤0.01%	1887
2025 Q4	$1.99M	Sell	75,498 -10,404	-12%	-$227K	﹤0.01%	1880
2025 Q3	$1.47M	Sell	85,902 -181	-0.2%	-$2.59K	﹤0.01%	2060
2025 Q2	$1.08M	Buy	86,083 +3,345	+4%	+$39.8K	﹤0.01%	2204
2025 Q1	$985K	Sell	82,738 -21,138	-20%	-$288K	﹤0.01%	2177
2024 Q4	$1.52M	Buy	103,876 +15,920	+18%	+$223K	﹤0.01%	2029
2024 Q3	$1.1M	Buy	87,956 +1,044	+1%	+$11.4K	﹤0.01%	2221
2024 Q2	$740K	Buy	86,912 +7,210	+9%	+$64.2K	﹤0.01%	2412
2024 Q1	$838K	Buy	79,702 +2,105	+3%	+$23.4K	﹤0.01%	2345
2023 Q4	$806K	Buy	77,597 +5,490	+8%	+$43.8K	﹤0.01%	2381
2023 Q3	$457K	Buy	72,107 +2,093	+3%	+$15.5K	﹤0.01%	2663
2023 Q2	$605K	Buy	+70,014	New	+$627K	﹤0.01%	2572

Other funds holding ZYME

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

RhumbLine Advisers's ZYME Position: Q2 2026 in Review

RhumbLine Advisers reduced its Zymeworks (ZYME) stake by 0.44% in Q2 2026, selling an estimated $8.46K and leaving 75,066 shares worth $1.96M. The position accounts for ﹤0.01% of the portfolio, ranked #1945.

RhumbLine Advisers first reported a position in ZYME in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.99M in Q4 2025. 202 funds tracked by Wall St. Rank hold ZYME as of Q2 2026.

RhumbLine Advisers held 75,066 shares of Zymeworks worth $1.96M as of Q2 2026.
RhumbLine Advisers sold 333 Zymeworks shares in Q2 2026, an estimated $8.46K.
Zymeworks made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1945 holding.
RhumbLine Advisers first reported a position in Zymeworks in Q2 2023 and has held it in 13 quarters since.
RhumbLine Advisers's Zymeworks position peaked at $1.99M in Q4 2025.
202 funds tracked by Wall St. Rank held Zymeworks as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.